ERBB2 and urinary bladder carcinoma: To evaluate the HER2-targeted therapy for recurrent bladder cancer patients with HER2 amplification (≥7 copy numbers) based on genetic testing, the phase II MATCH trial included recurrent bladder cancer patients that have progressed following at least one line of standard treatment of for which no agreed upon treatment approach exists.